Aplastic Anemia Market Overview
DelveInsight’s “Aplastic Anemia Market Insights, Epidemiology, and Market Forecast- 2036” report provides a comprehensive assessment of aplastic anemia, covering historical and forecasted epidemiology, treatment trends, emerging therapies, and market dynamics across the 7MM the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2022 to 2036.
The Aplastic Anemia market is shaped by a treatment landscape comprising hematopoietic stem cell transplantation (HSCT), immunosuppressive therapy (IST), and thrombopoietin receptor agonists. Market growth is expected to be tempered by the anticipated entry of generic PROMACTA and limited pipeline activity.
Discover comprehensive insights into aplastic anemia market trends, and future growth opportunities.
Aplastic Anemia Market Recent Developments
- February 2026: Ayrmid announced the presentation of additional positive results for OMISIRGE (omidubicel-onlv) in the treatment of severe aplastic anemia (SAA) at TANDEM 2026.
- On December 05, 2025 – Ayrmid Ltd., the parent company of Gamida Cell Inc. and a recognized leader in cell therapy innovation, announced that the U.S. Food and Drug Administration (FDA) has approved Omisirge (omidubicel-onlv) for the treatment of Severe Aplastic Anemia (SAA). This approval stems from an ongoing open-label, single-center study led by Dr. Richard Childs at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).
- In November 2025, Medical College of Wisconsin conducted a study is a prospective, multicenter Phase II study of hematopoietic stem cell transplantation for previously untreated patients with severe aplastic anemia (SAA). Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. Patients with aplastic anemia have low white blood cells (cells which fight infection), low red blood cells (cells that carry oxygen throughout the body), and low platelets (cells that help form clots and prevent bleeding). Treatments for SAA seeks to repair this abnormal immune system attack and allow the bone marrow to make the normal amount of blood cells. This can be done with a bone marrow transplant or with medications to suppress the immune system.
Leading Aplastic Anemia Companies
Key Aplastic Anemia Companies involved in the aplastic anemia treatment landscape include:
- Ayrmid (Gamida Cell)
- Teva Pharmaceuticals
- Kyowa Kirin
- Cellenkos
- Novartis
- Amgen, among others
Aplastic Anemia Overview: Classification and Disease Burden
Aplastic anemia is a rare and potentially life-threatening non-malignant hematologic disorder characterized by immune-mediated destruction or suppression of hematopoietic stem and progenitor cells. This results in pancytopenia and a markedly hypocellular bone marrow.The reported global incidence of aplastic anemia ranges from approximately 0.7 to 7.4 cases per million people annually, with higher incidence rates generally reported in Asian countries compared with Europe and the United States.
Explore the latest market research covering disease burden, treatment patterns, emerging cellular therapies, and the evolving aplastic anemia treatment landscape.
Aplastic Anemia Diagnosis: From Screening to Confirmation
The diagnosis of aplastic anemia requires an integrated assessment of clinical presentation, hematologic parameters, and bone marrow findings, while systematically excluding secondary and reversible causes.
Key Diagnostic Approaches
- Complete blood count and peripheral blood evaluation
- Bone marrow aspiration and biopsy
- Assessment of marrow cellularity
- Evaluation for malignant infiltration and fibrosis
- HLA typing for potential transplant candidates
- Molecular and cytogenetic testing to identify clonal abnormalities
- Evaluation for inherited bone marrow failure syndromes where appropriate
Definitive diagnosis generally relies on demonstrating a markedly hypocellular bone marrow with fatty replacement, accompanied by peripheral cytopenias and the absence of significant malignant infiltration or fibrosis.
Aplastic Anemia Approved Therapies
OMISIRGE (omidubicel-onlv) – Ayrmid (Gamida Cell)
OMISIRGE is a cord blood-derived hematopoietic stem cell therapy expanded using nicotinamide. It became an important development in the HSCT treatment landscape for severe aplastic anemia and is indicated for eligible adults and children aged 6 years and older who lack a compatible stem cell donor and undergo reduced-intensity conditioning.
ALVAIZ (eltrombopag choline) – Teva Pharmaceuticals
ALVAIZ is an oral thrombopoietin receptor agonist designed to increase platelet production through interaction with the transmembrane domain of the human TPO receptor. It received US FDA approval in November 2023 for certain indications, including severe aplastic anemia.
ROMIPLATE (romiplostim) – Kyowa Kirin
ROMIPLATE is a recombinant protein that stimulates the thrombopoietin receptor. The therapy was launched for aplastic anemia in Japan in June 2019, while the Japanese Ministry of Health, Labour and Welfare expanded its approved indication to aplastic anemia in September 2023.
PROMACTA/REVOLADE (eltrombopag) – Novartis
PROMACTA/REVOLADE has been a key contributor to the 7MM aplastic anemia market. The therapy received regulatory approvals across major markets for severe aplastic anemia, including approval in Europe in 2015 for IST-refractory SAA and subsequent approvals in Japan and the United States.
Aplastic Anemia Emerging Therapies
CK0801 – Cellenkos
CK0801 is an investigational allogeneic, cord blood-derived T-regulatory cell therapy designed to address immune dysfunction by inhibiting key drivers of inflammation.
The therapy is currently being evaluated in a Phase I clinical trial, and the US FDA granted Orphan Drug Designation in April 2025, highlighting its potential importance in addressing the unmet needs associated with aplastic anemia.
High Unmet Need Fueling Research and Development
Despite advances in transplantation and immunosuppressive treatment, substantial unmet needs remain across the aplastic anemia treatment landscape.
Key Unmet Needs Include:
- Transplant-related complications, including graft-versus-host disease and infections.
- Persistent mortality associated with HSCT and procedure-related complications.
- Suboptimal outcomes in elderly patients, who may have limited treatment options.
- Risk of relapse following immunosuppressive therapy.
- Limited clinical-stage pipeline activity.
- Need for treatments offering more durable responses and potentially curative outcomes.
- Limited clarity around optimal treatment strategies for older patients and individuals experiencing relapse.
These challenges are expected to continue influencing clinical decision-making and market dynamics through 2036.
Aplastic Anemia Market Drivers
Several factors are expected to support the evolution of the aplastic anemia market:
- Increasing incidence of aplastic anemia, particularly in Asian countries, is expected to expand the treated patient pool.
- OMISIRGE is reshaping the HSCT landscape by addressing limitations associated with conventional cord blood transplantation, including delayed engraftment.
- Greater exploration of androgens and growth factors, including G-CSF and erythropoietin, alongside established treatment regimens may improve marrow function.
- Thrombopoietin receptor agonists are expanding treatment options for IST-refractory and treatment-naïve patients.
- Continued advances in HSCT may increase preference for potentially curative treatment approaches.
- Growing understanding of disease biology may support the development of targeted and cellular therapies.
Aplastic Anemia Market Barriers
Despite these growth opportunities, several challenges could restrict market expansion:
- Transplant-related mortality and complications remain important concerns.
- Outcomes in elderly patients remain suboptimal despite improvements in transplantation safety.
- Limited pipeline activity may slow therapeutic innovation.
- The anticipated entry of generic PROMACTA is expected to create pricing pressure and reduce branded product revenues.
- Treatment strategies for older patients and patients experiencing relapse after IST remain areas of significant unmet need.
- Donor availability and eligibility for HSCT can restrict access to potentially curative treatment.
Gain access to DelveInsight’s detailed assessment of the Aplastic Anemia market
Conclusion
The Aplastic Anemia market reflects a persistent gap between the severity of disease burden and the limitations of currently available treatment options. While immunosuppressive therapy, thrombopoietin receptor agonists, and HSCT remain central to disease management, transplant-related complications, suboptimal outcomes in elderly patients, treatment access challenges, and limited pipeline activity continue to constrain the therapeutic landscape.
Explore DelveInsight’s comprehensive Aplastic Anemia Market Insights
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on the life sciences industry. The company provides comprehensive end-to-end solutions to pharmaceutical and biotechnology companies, helping them make informed strategic decisions, identify growth opportunities, and address complex business challenges.
Aplastic Anemia Market 2036: Novel Cell Therapies and Advances in Hematopoietic Transplantation Are Reshaping Treatment
#AplasticAnemiaMarket 2036 is witnessing gradual transformation as advances in hematopoietic stem cell transplantation, immunosuppressive therapy, thrombopoietin receptor agonists, and emerging cellular therapies address persistent unmet needs. According to DelveInsight, approximately 2,600 total incident cases of aplastic anemia were reported across the 7MM in 2025, highlighting the continued need for innovative treatment approaches.
